NPM1 and acute myeloid leukemia: Recurrent molecular aberrations like mutations in FLT3, NPM1, and CEBPA have been useful in prognostic sub classification of CN-AML and led to the inclusion of these markers in the revised WHO classification of AML in 2008 [42].